Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Stonepine Capital Management LLC

Stonepine Capital Management LLC decreased its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 19.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 999,790 shares of the company’s stock after selling 239,409 shares during the period. Milestone Pharmaceuticals makes up about 1.0% of Stonepine Capital Management LLC’s holdings, making the stock its 23rd biggest position. Stonepine Capital Management LLC owned approximately 1.88% of Milestone Pharmaceuticals worth $1,520,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BML Capital Management LLC lifted its stake in Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock valued at $1,727,000 after buying an additional 33,196 shares in the last quarter. Atria Investments Inc lifted its stake in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after buying an additional 12,430 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after buying an additional 10,000 shares in the last quarter. Finally, Lion Point Capital LP lifted its stake in Milestone Pharmaceuticals by 1.7% in the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock valued at $3,089,000 after buying an additional 40,000 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Trading Down 0.3 %

Shares of MIST stock traded down $0.01 during trading hours on Wednesday, hitting $1.85. 63,349 shares of the company were exchanged, compared to its average volume of 234,242. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals Inc. has a one year low of $1.12 and a one year high of $3.52. The business’s 50-day simple moving average is $1.60 and its two-hundred day simple moving average is $1.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. On average, equities research analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current year.

Analysts Set New Price Targets

MIST has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Monday, October 14th. Rodman & Renshaw initiated coverage on Milestone Pharmaceuticals in a report on Thursday, August 22nd. They set a “buy” rating and a $9.00 price objective for the company.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.